1,6-Dibromohexane | CAS:629-03-8

We serve 1,6-Dibromohexane CAS:629-03-8 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
1,6-Dibromohexane

Chemical Name:1,6-Dibromohexane
CAS.NO:629-03-8
Synonyms:Hexamethylene Bromide
1,6-Dibromohexan
Hexane, 1,6-dibromo-
HEXANE,1,6-DIBROMO
hexamethylene dibromide
Molecular Formula:C6H12Br2 
Molecular Weight:243.96700
 
Physical and Chemical Properties:
Density:1.586
Melting point:-2ºC
Boiling point:243ºC
Flash point:110ºC
Index of Refraction:1.507
 
Specification:
Appearance:Colorless to pale yellow transparent liquid
Assay(GC):≥99.0%
Moisture:≤0.1%
 
Packing:250 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Organic synthesis intermediate



Contact us for information like 1,6-Dibromohexane chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,hexamethylene dibromide physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,hexamethylene dibromide Use and application,hexamethylene dibromide technical grade,usp/ep/jp grade.


Related News: The Philippines, the United States and Australia have expanded travel restrictions, temporarily barring noncitizens who have recently traveled to China.Diethylcarbamyl chloride manufacturer It is frequently associated with the presence of blasts or leukemic cells in the marrow.4-[(4-hydroxy-6-oxo-1H-pyrimidin-2-yl)amino]benzonitrile supplier It is frequently associated with the presence of blasts or leukemic cells in the marrow.8-fluorooctan-1-ol vendor Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for cancer and immune disorders.According to statistics, in 2017, China’s total production of chemical drugs reached 3.478 million tons, a year-on-year increase of 1.6%. The main business income showed a steady increase, from 328.972 billion yuan in 2012 to 573.475 billion yuan in 2017. The total profit was 48.644 billion yuan, but profit margins remain low (8.48% in 2017).